Drugs / NY-ESO-1 T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01795976 | Oct 2014 → Nov 2017 | esophageal cancer | Fiona Thistlethwaite | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01795976 ↗ |
| Modality | Cell therapy | “This is a trial of adoptive T cell therapy using the patient's own T cells, genetically engineered to target the tumour associated antigen NY-ESO-1” NCT01795976 ↗ |